title: The role of glucocorticoid pulse therapy in pulmonary involvement in leptospirosis.
abstract: OBJECTIVE
  This study discusses incidence and clinical profile of pulmonary involvement in leptospirosis in South Gujarat. It also tries to evaluate the effect of high dose glucocorticoid pulse therapy (GPT) on it.
  
  
  METHODS
  A study was carried out on hundred and two patients of suspected leptospirosis, referred to Government Medical College, New Civil Hospital, Surat between June 99 to September 99. The incidence, clinical profile, and specific investigations were studied in patients having pulmonary involvement. Some of the patients were given high dose glucocorticoid pulse therapy. Their outcomes were compared with those who had not been given glucocorticoid pulse therapy.
  
  
  RESULTS
  Out of seventy seven seropositive patients 13 (16.8%) developed pulmonary involvement. Mortality was two out of eight patients in the group that received GPT and four out of five patients in the group that did not receive GPT. Two patients who died in the steroid treated group received the drug after 12 hours of onset of dyspnea.
  
  
  CONCLUSIONS
  High dose GPT should be given as early as possible after the onset of dyspnea to all the patients with pulmonary involvement in leptospirosis. Further studies are required to establish the GPT as a standard regimen in treatment of pulmonary involvement in leptospirosis.
authors.affiliation: Department of Medicine, Government Medical College, Surat.
authors.forename: S V
authors.initials: SV
authors.lastname: Trivedi
authors.forename: R K
authors.initials: RK
authors.lastname: Chavda
authors.forename: P Z
authors.initials: PZ
authors.lastname: Wadia
authors.forename: V
authors.initials: V
authors.lastname: Sheth
authors.forename: P N
authors.initials: PN
authors.lastname: Bhagade
authors.forename: S P
authors.initials: SP
authors.lastname: Trivedi
authors.forename: A M
authors.initials: AM
authors.lastname: Clerk
authors.forename: D M
authors.initials: DM
authors.lastname: Mevawala
mesh_terms: D000328:Adult; D000368:Aged; D004305:Dose-Response Relationship, Drug; D005260:Female; D005500:Follow-Up Studies; D005938:Glucocorticoids / Q000008:administration & dosage*; D006801:Humans; D007194:India; D007262:Infusions, Intravenous; D007922:Leptospirosis / Q000175:diagnosis / Q000188:drug therapy* / Q000401:mortality; D008297:Male; D008875:Middle Aged; D018410:Pneumonia, Bacterial / Q000188:drug therapy* / Q000382:microbiology* / Q000401:mortality; D011336:Probability; D011446:Prospective Studies; D020551:Pulse Therapy, Drug; D012016:Reference Values; D018570:Risk Assessment; D012720:Severity of Illness Index; D015996:Survival Rate; D016896:Treatment Outcome
chemical_list: D005938:Glucocorticoids